Zhejiang Shapuaisi PharmaceuticalLtd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

CEO

Zhejiang Shapuaisi PharmaceuticalLtd 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mingxiong Huang	Board Secretary & Director	2.8yrs	CN¥463.00k	0.067% CN¥ 2.0m
Guotong Xu	Independent Director	4.3yrs	CN¥100.00k	데이터 없음
Weimin Wang	Director	14.6yrs	CN¥7.00k	데이터 없음
Yuanlue Fu	Independent Director	4.3yrs	CN¥100.00k	데이터 없음
Xiao Feng	Employee Supervisor	9.5yrs	데이터 없음	데이터 없음
Jianguo Wu	Director	4.3yrs	CN¥379.20k	0.027% CN¥ 792.0k
Jiwei Sun	Independent Director	1.9yrs	CN¥96.60k	데이터 없음
Kai Lin	Director	1.5yrs	CN¥298.40k	0.027% CN¥ 792.0k

4.3yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: 603168 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

Zhejiang Shapuaisi PharmaceuticalLtd 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd., Annual General Meeting, May 15, 2024

Less than half of directors are independent

High number of new directors

Recent updates

Third quarter 2024 earnings released: CN¥0.014 loss per share (vs CN¥0.015 profit in 3Q 2023)

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.14 profit in 2Q 2023)

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend reduced to CN¥0.021

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd., Annual General Meeting, May 15, 2024

New minor risk - Earnings quality

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment deteriorates as stock falls 20%

Investor sentiment deteriorates as stock falls 18%

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Investor sentiment deteriorates as stock falls 19%

Less than half of directors are independent

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.023 in 2Q 2022)

High number of new directors

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Third quarter 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.029 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.023 (vs CN¥0.051 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.03 in 1Q 2021)

Full year 2021 earnings released: EPS: CN¥0.11 (vs CN¥0.56 loss in FY 2020)

Second quarter 2021 earnings released: EPS CN¥0.051 (vs CN¥0.046 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.56 loss per share (vs CN¥0.024 profit in FY 2019)

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: CN¥6.59

New 90-day low: CN¥7.18

Third quarter earnings released

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168) completed the acquisition of Taizhou Women and Children's Hospital Co., Ltd. from Shanghai Yuxie Medical Management Co., Ltd. and Shanghai Xiehe Hospital Investment Management Co., Ltd.

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168) intends to acquire Taizhou Women and Children's Hospital Co., Ltd. from Shanghai Yuxie Medical Management Co., Ltd. and Shanghai Xiehe Hospital Investment Management Co., Ltd. for approximately CNY 500 million.

New 90-day high - CN¥9.58

First half earnings released

First half earnings released

New 90-day high - CN¥9.38

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

이사회 구성원

평균 재임 기간

평균 연령